Akero Therapeutics Inc (AKRO)
18.82
+0.51
(+2.79%)
USD |
NASDAQ |
May 31, 16:00
18.84
+0.02
(+0.11%)
After-Hours: 20:00
Akero Therapeutics SG&A Expense (Annual): 31.07M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 31.07M |
| December 31, 2022 | 29.87M |
| December 31, 2021 | 19.13M |
| Date | Value |
|---|---|
| December 31, 2020 | 15.24M |
| December 31, 2019 | 8.605M |
| December 31, 2018 | 1.896M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
8.605M
Minimum
2019
31.07M
Maximum
2023
20.78M
Average
19.13M
Median
2021
SG&A Expense (Annual) Benchmarks
| 89bio Inc | 28.97M |
| Madrigal Pharmaceuticals Inc | 108.15M |
| Viking Therapeutics Inc | 37.02M |
| Eli Lilly and Co | 6.941B |
| Ionis Pharmaceuticals Inc | 232.60M |